...
首页> 外文期刊>SN Applied Sciences >Hepatoprotective activity of the ethanolic extract of Morus indica roots from Indian Bodo tribes
【24h】

Hepatoprotective activity of the ethanolic extract of Morus indica roots from Indian Bodo tribes

机译:印度菩提地区森林籼稻乙醇提取物的肝保护活性

获取原文
获取原文并翻译 | 示例

摘要

The roots of Morus species are well described in the Pharmacopoeia of the People's Republic of China (ChP) for its traditional use in treating liver fibrosis due to its hepatoprotective property. However, little is known about the hepatoprotective effect of the roots of Morus indica L. (RoMi), and the pharmacological mechanism(s) are uncertain due to its intricacy. Therefore, this study evaluates the hepatoprotective activity of the ethanolic extract of RoMi (eRoMi) against the CCl4-induced in-vivo animal model at different dosages (100 and 200 mg/kg BW) in comparison with silymarin as a positive control. The hepatoprotective activity of eRoMi was evaluated by measuring the levels of serum biomarkers, hepatic antioxidant enzymes and was verified by histological studies. Interestingly, 1,2-bis(trimethylsilyl) benzene, 1,4-phenylenebis (trimethylsilane), 2,4,6-cycloheptatriene-1-one, 3,5-bis-trimethylsilyl and alpha-amyrin were the active components found in eRoMi as detected by GC-MS. Oral administration of eRoMi (200 mg/kg BW) to rats significantly protected serum biochemical parameters (increased ALT, AST, LDH, bilirubin and GGT as well as depletion of antioxidant enzymes and hepatic GSH) and elevation in hepatic lipid peroxidation as compared to CCl4-treated rats. The hematological indices such as erythrocytes, hemoglobin, monocytes and lymphocytes were also normal in eRoMi-treated rats. The histopathological evaluation indicated a significant restoration of liver structure as compared to silymarin. This study is the first scientific validation for the traditional use of eRoMi to understand its hepatoprotective activity.
机译:森属物种的根源在中华人民共和国(CHP)的药典中,为其传统用于治疗肝脏纤维化而导致的肝脏保护性。然而,关于Morus indica L.(ROMI)的根源的肝脏保护作用很少,并且由于其复杂性,药理机制不确定。因此,该研究评估了与西方西兰林作为阳性对照的不同剂量(100和200mg / kg bw)对不同剂量(100和200mg / kg bw)的CCL4诱导的CCL4诱导的体内动物模型的乙二醇提取物的肝脏药物活性。通过测量血清生物标志物,肝抗氧化酶的水平,通过组织学研究验证EROMI的肝保护活性。有趣的是,1,2-双(三甲基甲硅烷基)苯,1,4-亚苯基(三甲基硅烷),2,4,6-环庚烷 - 1-一,3,5-双三甲基甲硅烷基和α-奥霉素是发现的活性成分由GC-MS检测到的EROMI。与CCl4相比,对大鼠的Oromi(200mg / kg bw)对大鼠的血清生物化学参数(增加Alt,Ast,LDH,胆红素和GHT)以及抗氧化酶和肝脏GSH的枯萎病,与CCl4相比,肝脂质过氧化的升高 - 治疗大鼠。在EROMI处理的大鼠中,血液学指数如红细胞,血红蛋白,单核细胞和淋巴细胞也正常。组织病理学评估表明与西米兰林相比,肝脏结构的显着恢复。本研究是传统使用EROMI来了解其HeptoPoteccective活动的第一个科学验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号